Advanced search
Publication Cover
Therapeutic Delivery Volume 9, 2018 - Issue 10
Submit an article Journal homepage
2,973
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Emerging Therapeutic Nanotechnologies in Pancreatic cancer: advances, Risks and Challenges

Ana Rebelo1 CBIOS, Universidade Lusófona de Humanidades e Tecnologias, Department of Sciences & Health Technologies (ECTS), Campo Grande 376, Lisboa, 1749-024, Portugal;2 Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Ctra. A2 km 33,600 Campus Universitario28871, Alcalá de Henares, Spain
&
Catarina Reis3 iMed. ULisboa–Faculdade de Farmácia, Department of Galenic Pharmacy and Pharmaceutical Technology (DFGTF), Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa, 1649-003, Portugal;4 IBEB, Faculdade de Ciências, Universidade de Lisboa, Lisboa, 1749-016, PortugalCorrespondence[email protected]
Pages 691-694 | Received 08 Jul 2018, Accepted 21 Aug 2018, Published online: 02 Oct 2018

References

  • Teague A Lim KH Wang-Gillam A . Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther. Adv. Med. Oncol.7 (2), 68–84 (2015).
  • Manzur A Oluwasanmi A Moss D Curtis A Hoskins C . Nanotechnologies in pancreatic cancer therapy. Pharmaceutics9 (4), 39 (2017).
  • Rebelo A Molpeceres J Rijo P Reis CP . Pancreatic cancer therapy review: from classic therapeutic agents to modern nanotechnologies. Curr. Drug Metab.18 (4), 346–359 (2017).
  • Zhou J Lindsey E Stojadinovic A et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control21 (6), 853–861 (2010).
  • Zhu Q Pan X Sun Y et al. Biological nanoparticles carrying the Hmda-7 gene are effective in inhibiting pancreatic cancer in vitro and in vivo. PLoS ONE12 (10), 1–12 (2017).
  • Birhanu G Javar HA Seyedjafari E Zandi-Karimi A . Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed. Pharmacother.88, 635–643 (2017).
  • Sielaff CM Mousa SA . Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J. Cancer Res. Clin. Oncol.144 (7), 1205–1217 (2018).
  • Hackeng WM Hruban RH Offerhaus GJA Brosens LAA . Surgical and molecular pathology of pancreatic neoplasms. Diagn. Pathol.11 (47), 1–17 (2016).
  • Ilic M Ilic I . Epidemiology of pancreatic cancer. World J. Gastroenterol.22 (44), 9694–9705 (2016).
  • Karanikas M Esempidis A Tzoutze Memet Chasan Z et al. Pancreatic cancer from molecular pathways to treatment opinion. J. Cancer7 (10), 1328–1339 (2016).
  • Collisson EA Olive KP . Pancreatic cancer: progress and challenges in a rapidly moving field. Cancer Res.77 (5), 1060–1062 (2017).
  • Sinha R . Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther.5 (8), 1909–1917 (2006).
  • Bertrand N Wu J Xu X Kamaly N Farokhzad OC . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev.66, 2–25 (2014).
  • ud Din F Aman W Ullah I et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomedicine12, 7291–7309 (2017).
  • Alexis F Rhee JW Richie JP Radovic-Moreno AF Langer R Farokhzad OC . New frontiers in nanotechnology for cancer treatment. Urol. Oncol.26 (1), 74–85 (2008).
  • McCarroll J Teo J Boyer C Goldstein D Kavallaris M Phillips PA . Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front. Physiol.5 (2), 1–10 (2014).
  • Adiseshaiah PP Crist RM Hook SS McNeil SE . Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat. Rev. Clin. Oncol.13 (12), 750–765 (2016).
  • Bisht S Mizuma M Feldmann G et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc™) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther.9 (8), 2255–2264 (2011).
  • Ventola CL . The nanomedicine revolution: part 3: regulatory and safety challenges. P T37 (11), 631–639 (2012).
  • Ventola CL . Progress in nanomedicine: approved and investigational nanodrugs. P T42 (12), 742–755 (2017).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.